Open Access

Accuracy of 18F‑FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta‑analysis

  • Authors:
    • Zhicheng Zhang
    • Bo Zheng
    • Wei Chen
    • Hui Xiong
    • Caiming Jiang
  • View Affiliations

  • Published online on: December 21, 2020     https://doi.org/10.3892/etm.2020.9595
  • Article Number: 164
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Contrast‑enhanced computed tomography (CECT) is commonly used for staging and diagnosing recurrent gastric cancer. Recently, 18F‑fluorodeoxyglucose positron emission tomography (18F‑FDG PET)/CT gained popularity as a diagnostic tool owing to advantages including dual functional and anatomical imaging, which may facilitate early diagnosis. The diagnostic performance of 18F‑FDG PET/CT and CECT has been assessed in several studies but with variable results. Therefore, the present meta‑analysis aimed to evaluate the accuracy of 18F‑FDG PET/CT and CECT for primary TNM staging and the diagnosis of recurrent gastric cancers. A systematic search of the PubMed Central, Medline, Scopus, Cochrane and Embase databases from inception until January 2020 was performed. The Quality Assessment of Diagnostic Accuracy Study‑2 tool was used to determine the quality of the selected studies. Pooled estimates of sensitivity and specificity were calculated. A total of 58 studies comprising 9,997 patients were included. Most studies had a low risk of bias. The sensitivity and specificity for nodal staging of gastric cancer were 49% (95% CI, 37‑61%) and 92% (95% CI, 86‑96%) for 18F‑FDG PET/CT, respectively, and 67% (95% CI, 57‑76%) and 86% (95% CI, 81‑89%) for CECT, respectively. For metastasis staging, the sensitivity and specificity were 56% (95% CI, 40‑71%) and 97% (95% CI, 87‑99%) for 18F‑FDG PET/CT, respectively, and 59% (95% CI, 41‑75%) and 96% (95% CI, 83‑99%) for CECT, respectively. For diagnosing cancer recurrence, the pooled sensitivity and specificity were 81% (95% CI, 72‑88%) and 83% (95% CI, 74‑89%) for 18F‑FDG PET/CT, respectively, and 59% (95% CI, 41‑75%) and 96% (95% CI, 83‑99%) for CECT, respectively. Both 18F‑FDG PET/CT and CECT were deemed highly useful for diagnosing recurrent gastric cancer due to their high sensitivities and specificities. However, these techniques cannot be used to exclude or confirm the presence of lymph node metastases or recurrent gastric cancer tumors, but can be used for the confirmation of distal metastasis.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 21 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Z, Zheng B, Chen W, Xiong H and Jiang C: Accuracy of <sup>18</sup>F‑FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta‑analysis. Exp Ther Med 21: 164, 2021.
APA
Zhang, Z., Zheng, B., Chen, W., Xiong, H., & Jiang, C. (2021). Accuracy of <sup>18</sup>F‑FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta‑analysis. Experimental and Therapeutic Medicine, 21, 164. https://doi.org/10.3892/etm.2020.9595
MLA
Zhang, Z., Zheng, B., Chen, W., Xiong, H., Jiang, C."Accuracy of <sup>18</sup>F‑FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta‑analysis". Experimental and Therapeutic Medicine 21.2 (2021): 164.
Chicago
Zhang, Z., Zheng, B., Chen, W., Xiong, H., Jiang, C."Accuracy of <sup>18</sup>F‑FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta‑analysis". Experimental and Therapeutic Medicine 21, no. 2 (2021): 164. https://doi.org/10.3892/etm.2020.9595